Clinically, the anti-angiogenic treatment sorafenib—one of the first-line agents to treat HCC—is associated with an increase in TANs that produce CCL2 and CCL17, which can establish immunosuppressive niches within the TME to promote tumor cell survival. This evidence concerns the gene CCL17 and neoplasm.